Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mammary Neoplasms, Human”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT01358877
What this trial is testing

Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 4,804
Not applicableStudy completedNCT02913456
What this trial is testing

A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)

Who this might be right for
Breast Cancer
Hoffmann-La Roche 629
Early research (Phase 1)Looking for participantsNCT07117214
What this trial is testing

A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers

Who this might be right for
Breast NeoplasmsCarcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 36
Early research (Phase 1)Looking for participantsNCT06638307
What this trial is testing

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Stemline Therapeutics, Inc. 240
Testing effectiveness (Phase 2)Looking for participantsNCT06993844
What this trial is testing

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsAdvanced Breast Cancer
Ensem Therapeutics 233
Early research (Phase 1)Ended earlyNCT05035407
What this trial is testing

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Who this might be right for
Kita-kyushu Lung Cancer Antigen 1, Human
National Cancer Institute (NCI) 36
Early research (Phase 1)Study completedNCT00800436
What this trial is testing

A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females

Who this might be right for
Breast Cancer
Hoffmann-La Roche 66
Early research (Phase 1)Looking for participantsNCT05283330
What this trial is testing

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Who this might be right for
Cervical CancerBreast CancerColon Cancer+4 more
Orano Med Theranostics, SAS 48
Large-scale testing (Phase 3)Study completedNCT00073528
What this trial is testing

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Novartis Pharmaceuticals 1,286
Early research (Phase 1)Ended earlyNCT05489679
What this trial is testing

AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 6
Early research (Phase 1)Study completedNCT00426530
What this trial is testing

Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

Who this might be right for
Breast NeoplasmsNeoplasm Metastasis
Novartis Pharmaceuticals 50
Testing effectiveness (Phase 2)Ended earlyNCT03729596
What this trial is testing

MGC018 With or Without MGA012 in Advanced Solid Tumors

Who this might be right for
Squamous Cell Carcinoma of Head and NeckTriple Negative Breast CancerMelanoma+3 more
MacroGenics 143
Early research (Phase 1)Active Not RecruitingNCT03821935
What this trial is testing

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumors Cancer
AbbVie 364
Early research (Phase 1)Study completedNCT05203497
What this trial is testing

Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ZHER2

Who this might be right for
Breast Cancer Female
Tomsk National Research Medical Center of the Russian Academy of Sciences 30
Not applicableStudy completedNCT07471113
What this trial is testing

Mobile App-Supported HPV and Breast Cancer Awareness Program

Who this might be right for
Human Papilloma VirusBreast CancerWomen
Ataturk University 70
Testing effectiveness (Phase 2)Looking for participantsNCT05735080
What this trial is testing

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Who this might be right for
Breast CancerBreast Cancer MetastaticHormone Receptor Positive Tumor+6 more
Incyclix Bio 150
Testing effectiveness (Phase 2)Study completedNCT03280563
What this trial is testing

Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Who this might be right for
Breast Neoplasms
Hoffmann-La Roche 144
Testing effectiveness (Phase 2)Ended earlyNCT05180474
What this trial is testing

GEN1047 for Solid Tumors - First in Human (FIH) Trial

Who this might be right for
Breast Cancer, Breast NeoplasmsEndometrial Cancer, Endometrial NeoplasmOvarian Cancer, Ovarian Neoplasms+1 more
Genmab 179
Testing effectiveness (Phase 2)Ended earlyNCT06408168
What this trial is testing

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

Who this might be right for
Hormone Receptor-positive Human Epidermal Growth Factor 2-negativeMetastatic Invasive LObular Carcinoma
M.D. Anderson Cancer Center 6
Not applicableEnded earlyNCT04967248
What this trial is testing

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

Who this might be right for
Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
Novartis Pharmaceuticals 4
Next Page